- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Report
- July 2024
- 231 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- April 2025
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Clinical Trials
- December 2024
- 80 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- May 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,238GBP
- Report
- October 2023
- 85 Pages
United States
From €4414EUR$4,850USD£3,784GBP
- Report
- May 2022
- 196 Pages
Global
From €2389EUR$2,625USD£2,048GBP
€4778EUR$5,250USD£4,096GBP
- Report
- October 2022
- 270 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- February 2022
- 210 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- June 2023
- 112 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2024
- 120 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- July 2022
- 225 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- April 2022
- 188 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- January 2024
- 138 Pages
United States
€3458EUR$3,800USD£2,965GBP
- Report
- January 2023
- 27 Pages
Global
€11149EUR$12,250USD£9,558GBP

Xeljanz (tofacitinib) is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, which works by blocking certain proteins that are involved in the body's inflammatory response. Xeljanz is taken orally, usually twice daily, and is available in both tablet and suspension form. It is typically used in combination with other medications, such as methotrexate or biologic drugs.
Xeljanz is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It has become a popular treatment option for immune disorders, due to its effectiveness and convenience.
Companies in the Xeljanz market include Pfizer, which manufactures and markets the drug, as well as other pharmaceutical companies that produce generic versions of the drug. Additionally, there are numerous companies that provide support services, such as patient assistance programs and educational materials. Show Less Read more